Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative (Q44468657)

3 December 2017

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative (English)

1 reference

3 December 2017

1 reference

Henrik Agersø

1

1 reference

PubMed ID

12791417

3 December 2017

Paolo Vicini

series ordinal

2

1 reference

PubMed ID

12791417

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

European Journal of Pharmaceutical Sciences

3 December 2017

1 reference

3 December 2017

19

1 reference

3 December 2017

141-150

1 reference

3 December 2017

2-3

1 reference

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-0987%2803%2900073-3

7 January 2021

10.1016/S0928-0987(03)00073-3

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12791417